Cargando…
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Although great success has been obtained in the clinic, the current immune checkpoint inhibitors still face two challenging problems: low response rate and immune-related adverse effects (irAEs). Here we report the combination of immunogenic chemotherapy and locally expressed PD-L1 trap fusion prote...
Autores principales: | Song, Wantong, Shen, Limei, Wang, Ying, Liu, Qi, Goodwin, Tyler J., Li, Jingjing, Dorosheva, Olekasandra, Liu, Tianzhou, Liu, Rihe, Huang, Leaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993831/ https://www.ncbi.nlm.nih.gov/pubmed/29884866 http://dx.doi.org/10.1038/s41467-018-04605-x |
Ejemplares similares
-
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
por: Das, Manisit, et al.
Publicado: (2020) -
Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy
por: Hu, Mengying, et al.
Publicado: (2019) -
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022) -
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma
por: Guo, Jianfeng, et al.
Publicado: (2021) -
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Zhang, Hongji, et al.
Publicado: (2021)